Synlogic’s C-Suite Adds Richard Riese, CFO Todd Shegog to Depart

Synlogic (NASDAQ: [[ticker:SYBX]]) has appointed Richard Riese to serve as chief medical officer. Riese was most recently vice president of clinical development at Alnylam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]). In other moves, Synlogic announced that Todd Shegog, the company’s chief financial officer, will leave on Sept. 18 to pursue another opportunity. In a securities filing, Synlogic said Shegog’s resignation was not the result of any disagreement with the company. Synlogic is developing “living medicines” comprised of engineered bacteria. In June, the company secured an $80 million equity investment from Ginkgo Bioworks to support its research.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan